What about Novavax? Vaccine company’s booster is left out of FDA action on Pfizer, Moderna shots

The FDA’s ac­tion Mon­day clear­ing Mod­er­na and Pfiz­er/BioN­Tech’s lat­est mR­NA-based Covid-19 boost­ers begged a very large ques­tion: Why didn’t the agency act on No­vavax’s boost­er?

The agency’s an­nounce­ment made no men­tion of No­vavax’s shot, de­spite the com­pa­ny sub­mit­ting its boost­er ap­pli­ca­tion and ex­pect­ing a de­ci­sion soon. Al­though an ACIP meet­ing is sched­uled Tues­day to set a rec­om­men­da­tion for this year’s boost­ers, No­vavax said it doesn’t ex­pect to get an an­swer be­fore then.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.